纳武利尤单抗联合伊匹木单抗联合或不联合序贯或同步立体定向放疗治疗黑色素瘤脑转移患者:一项国际回顾性研究
这项国际回顾性研究纳入453例无症状黑色素瘤脑转移患者,评估纳武利尤单抗联合伊匹木单抗(COMBO)联合或不联合立体定向放疗(SRT)的结局。多因素分析显示序贯SRT与同步SRT均与OS改善相关,同步与序贯SRT之间无显著差异,放射性坏死发生率为10.3%。作者认为SRT联合COMBO与更好的OS相关,但需前瞻性研究验证。
要点
- 多因素分析中序贯SRT对比未放疗HR 0.45(0.32-0.64),同步SRT对比未放疗HR 0.48(0.33-0.69)。
- 同步SRT与序贯SRT之间OS无显著差异。
- 中位随访29个月,总体人群中位OS为17.8个月,放射性坏死发生率为10.3%。
核心结论
- 作者认为接受SRT联合COMBO的患者OS更好,与SRT时机无关;需前瞻性研究验证该发现。
研究设计与样本
- 国际回顾性研究,纳入453例接受COMBO联合或不联合SRT的黑色素瘤脑转移患者:190例仅接受COMBO,107例接受COMBO联合同步SRT,156例接受COMBO联合序贯SRT。
主要发现
- 多因素分析中,治疗线数>1线对比1线HR 2.60(1.93-3.50),序贯SRT对比未放疗HR 0.45(0.32-0.64),同步SRT对比未放疗HR 0.48(0.33-0.69),使用类固醇HR 1.56(1.17-2.08),年龄HR 1.01(1.00-1.02),基线脑转移数目≥3个对比1个HR 1.55(1.11-2.17),2个对比1个HR 1.53(1.02-2.31),均与OS相关。
- 接受同步SRT与序贯SRT的患者之间无显著差异。
- 中位随访29个月,总体人群中位OS为17.8个月;接受SRT者中,序贯放疗患者中位OS为27.3个月(15.3-39.4),同步放疗患者中位OS为22.2个月(12.7-31.7)。
- 放射性坏死发生率为10.3%,毒性反应与既往研究一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需前瞻性研究验证该发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ipilimumab plus nivolumab (COMBO) is the standard treatment in patients with asymptomatic melanoma brain metastases (MBM). We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO with or without sequential/concomitant stereotactic radiotherapy (SRT). METHODS: MBM patients treated with COMBO with or without SRT have been retrieved: demographics, steroid treatment, Central Nervous System [CNS]-related symptoms, BRAF status, radiotherapy (yes/no and timing) or surgery, number of MBM, maximum diameter of metastasis, overall response rate (ORR), progression-free (PFS) and overall survival (OS) have been analyzed. RESULTS: 453 patients were included: 190 received COMBO alone, 107 received COMBO and concomitant SRT, 156 COMBO and sequential SRT, respectively. At multivariable analysis the line of treatment [> 1st vs 1st: HR 2.60 (1.93-3.50)], sequential SRT vs no radiotherapy [HR 0.45 (0.32-0.64)], concomitant SRT vs no radiotherapy [HR 0.48 (0.33-0.69)], steroids [HR 1.56 (1.17-2.08)], age [HR 1.01 (1.00-1.02)] and number of MBM [≥ 3 vs 1 HR 1.55 (1.11-2.17)), 2 vs 1 HR 1.53 (1.02-2.31)] at baseline were associated with OS. There was no significant difference between patients who received concomitant vs sequential SRT. At a median follow-up of 29 months, the median-OS in the overall population was 17.8 months while in those who received SRT was 27.3 (15.3-39.4) for patients receiving sequential radiotherapy and 22.2 (12.7-31.7) for those receiving radiotherapy concomitantly to COMBO. The incidence of radionecrosis was 10.3 %. Toxicities were consistent with previous studies. CONCLUSIONS: Our results suggest a better OS in patients who receive SRT plus COMBO, regardless of timing of SRT. Prospective studies are needed to validate our findings.
引用
- Mandalà M, Amaral T, Rutkowski P, et al. Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study. Eur J Cancer. 2025. PMID: 40505525. doi:10.1016/j.ejca.2025.115567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。